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The endocannabinoid system (ECS) exerts a modulatory effect of important functions 
such as neurotransmission, glial activation, oxidative stress, or protein homeostasis. 
Dysregulation of these cellular processes is a common neuropathological hallmark in 
aging and in neurodegenerative diseases of the central nervous system (CNS). The 
broad spectrum of actions of cannabinoids allows targeting different aspects of these 
multifactorial diseases. In this review, we examine the therapeutic potential of the ECS 
for the treatment of chronic neurodegenerative diseases of the CNS focusing on 
Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral 
sclerosis. First, we describe the localization of the molecular components of the ECS 
and how they are altered under neurodegenerative conditions, either contributing to or 
protecting cells from degeneration. Second, we address recent advances in the 
modulation of the ECS using experimental models through different strategies including 
the direct targeting of cannabinoid receptors with agonists or antagonists, increasing the 
endocannabinoid tone by the inhibition of endocannabinoid hydrolysis, and activation 
of cannabinoid receptor-independent effects. Preclinical evidence indicates that 
cannabinoid pharmacology is complex but supports the therapeutic potential of 
targeting the ECS. Third, we review the clinical evidence and discuss the future 
perspectives on how to bridge human and animal studies to develop cannabinoid-based 
therapies for each neurodegenerative disorder. Finally, we summarize the most relevant 
opportunities of cannabinoid pharmacology related to each disease and the multiple 
unexplored pathways in cannabinoid pharmacology that could be useful for the 








AD: Alzheimer’s disease 
AEA: anandamide 
2-AG: 2-arachidonoylglycerol 
ALS: amyotrophic lateral sclerosis 
APP: amyloid precursor protein 
BBB: blood–brain barrier 
BDNF: brain-derived neurotrophic factor 
CB1: cannabinoid receptor type-1  
CB2: cannabinoid receptor type-2 
CBD: cannabidiol 
CBG: cannabigerol 
CNS: central nervous system  
DAGL: diacylglycerol lipase 
ECS: endocannabinoid system 
FAAH: fatty acid amide hydrolase 
FTD: frontotemporal lobar dementia 
FUS: fused in sarcoma protein 
GPe: external segment of the globus pallidus 
GPi: internal segment of the globus pallidus 
GSK3β: glycogen synthase kinase 3β 
HD: Huntington’s disease 
L-dopa: L-3,4-dihydroxyphenylalanine 





MAGL: monoacylglycerol lipase 
MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
NAPE-PLD: N-arachidonoyl-phosphatidylethanolamine phospholipase D 
NMDA: N-methyl D-aspartate 
NO: nitric oxide 
iNOS: inducible nitric oxide synthase 
PET: positron emission tomography 
PD: Parkinson’s disease 
PPARγ: peroxisome proliferator-activated receptor γ 
ROS: reactive oxygen species 
SN: substantia nigra 
SNpc: substantia nigra pars compacta  
SNpr: substantia nigra pars reticulata 
SOD: superoxide dismutase 
STN: subthalamic nucleus 







1. Common features and challenges in the cannabinoid research in 
neurodegenerative diseases 
Neurodegenerative diseases affecting the central nervous system (CNS), such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), 
amyotrophic lateral sclerosis (ALS), and others, are characterized by the progressive 
loss of specific neuronal subpopulations that affect selective regions of the brain and the 
spinal cord and neurotransmitter systems, thereby leading to different clinical features 
[1]. Because aging is the major risk factor for these diseases, the prevalence of 
degenerative disorders of the CNS is expected to increase in the next decades [2]. 
Currently, there is no cure for any of these disorders. Available treatments provide 
transient temporary symptomatic relief, but they are poorly active in the underlying 
disease progression. Seeking molecules with disease-modifying activity is one of the 
greatest challenges demanded by patients affected by these diseases [3]. Abnormal 
protein accumulation, impairment of the lysosomal system, excitotoxicity, oxidative 
stress, and neuroinflammation are classic hallmarks of the aged brain and 
neurodegenerative conditions [4]. The endocannabinoid system (ECS) has the ability to 
modulate these common traits in neurodegeneration, thus emerging as a viable target for 
symptom alleviation or disease progression based on pharmacological modulation of 
endocannabinoid signaling [5]. Cannabinoids provide a broad-spectrum profile, which 
is particularly interesting when dealing with complex pathologies of multifactorial 
origin [6]. The pleiotropic properties of cannabinoids confer the cannabinoids as 
important molecules for the development of neuroprotective strategies. 
Endocannabinoid signaling involves cannabinoid receptor-dependent effects (e.g., 
activation of cannabinoid type-1 (CB1) receptors to normalize glutamate homeostasis or 




proliferator-activated receptor γ (PPARγ), or modulation of G-protein receptor 55 
(GPR55) to reduce local inflammatory events) and also cannabinoid receptor-
independent effects to reduce oxidative stress, all of which may ultimately promote 
neuron survival [7]. The key localization of ECS elements in the CNS and their 
alteration under pathological conditions suggest that this system participates in crucial 
processes for balancing neurodegeneration/neuroprotection (Fig. 1). This review focuses 
on how the components of the ECS are altered in chronic degenerative diseases 
affecting the CNS, such as AD, PD, HD, and ALS (see footnote #1), and indicates that 
bioactivity of endocannabinoid-based therapies is likely to vary depending on the 
disease type and the stage at the time of treatment. The review emphasizes on recent 
advances in preclinical evidence that provides scientific support to propose 
cannabinoids for the treatment of different neurodegenerative conditions and discusses 
the future perspectives of cannabinoid-based therapies for the treatment of each 
neurological disorder. 
 
2. Cannabinoid pharmacology in Alzheimer’s disease 
AD is the most common form of dementia among the elderly, and it is defined as a 
progressive decline of cognition, memory, and other mental functions. The 
morphological hallmarks of brains affected by AD include amyloid-beta (Aβ) plaques 
and neurofibrillary tangles composed of hyperphosphorylated microtubule-associated 
tau protein, which induce neuronal death and impaired interneuronal communication, 
FOOTNOTE #1: 
Other neurological disorders with degenerative components (e.g., multiple sclerosis and spinal injury) 
affecting the peripheral nervous system rather than the central nervous system have been reviewed in 




and these hallmarks progress from the brain stem and inner parts of the temporal lobes 
to the major part of the whole telencephalon [8]. In fact, most of the experimental 
models of AD are based on exogenous administration or genetic manipulation for 
overexpressing Aβ and/or hyperphosphorylated tau in cell cultures or rodent models [9]. 
Although they have some limitations because they do not fully replicate the AD 
pathology, those experimental models based on Aβ and/or hyperphosphorylated tau 
have significantly contributed to AD research.  
However, other multiple alterations converge in the pathogenesis of AD, including 
synaptic degeneration, mitochondrial defects, and increased production of reactive 
oxygen species (ROS). In addition, inflammatory responses to protein 
aggregation/deposition, altered neurotransmission, and production of other 
neuromodulators, together with a vascular dysfunction and impaired degradation 
pathways, are assumed to play crucial roles in AD progression also [10][11]. Current 
available therapies against AD produce mild improvement of cognitive and functional 
capacities [12]. These therapies act on a single target and are administered after clinical 
manifestations, when there is no turning back for certain pathological events. The 
progression from early stages of the neurodegenerative process to symptomatic stages 
may take decades, whereas once the dementia symptoms appear, the disease progression 
accelerates causing devastating effects [10]. Therefore, two of the major goals of current 
research in AD are to develop new tools for early diagnosis and to search for treatments 
that are more effective aimed at curbing or retarding disease progression toward 
dementia by acting on multiple targets during the prodromal period of the disease. 
In this context, targeting the ECS has attracted growing interest during the last decade 
based on the numerous findings revealing that the stimulation of ECS contributes to 




stages of AD, thereby conferring cannabinoid compounds a potential utility against this 
neurodegenerative disease, as summarized below. 
 
2.1. The endocannabinoid system in Alzheimer’s disease  
Neuropathological changes in AD trigger a potent neuroinflammatory reaction in which 
glial cells (astrocytes and microglia) become a source of increased cytokine production 
[13]. In this context, the ECS becomes profoundly altered, with modifications ranging 
from changes in anandamide (AEA) and 2-arachidonoylglycerol (2-AG) levels to the 
expression pattern of their regulatory enzymes and of cannabinoid receptors [14]. 
A seminal study by Westlake et al [15] showed a significant decrease in CB1 receptors 
in tissue sections from AD donors, as measured by autoradiography, probably because 
of the neuronal loss associated with this disease. Further studies, however, have not 
confirmed these observations. For instance, no changes in CB1 receptor levels were 
found by immunoblotting and receptor binding in human brain samples [16]. In addition, 
an in vivo study conducted in 11 patients with AD and 7 healthy volunteers by using the 
specific radiotracer [18F]MK-9470 for positron emission tomography (PET) of CB1 
receptors found no significant differences in CB1 receptor availability in any of the 
brain regions studied [17]. It is relevant to note that a hyperactivated state of CB1 
receptor in the early stages of AD, followed by a significant decrease as the disease 
progresses, has been reported, thus suggesting that CB1 receptor might have therapeutic 
potential in the progression of the disease [18].  
Data obtained in mouse models of AD have thus far not been conclusive either. 
Different groups have reported increases [19], decreases [20], or no changes [21] in CB1 
receptor levels in several brain areas (at the mRNA, protein, or receptor coupling 




a role in the progression of AD, but it is difficult to establish the precise role(s) in which 
they might contribute. These could range from modifying amyloid processing to protect 
neurons in the risk of degeneration or to dampen inflammation (see below). 
Perhaps, one of the most intriguing aspects of these changes is the profound alteration in 
the expression pattern of CB2 receptors, which takes place in AD. The analysis of 
human AD samples by immunohistochemistry revealed the absence of signal for CB2 
receptors in brains of the control group (with a limited presence in a subset of microglial 
cells such as the perivascular microglia) but an intense level of staining in AD samples 
[22]. Colocalization studies confirmed that CB2 receptors were expressed in microglial 
cells only, located in the surrounding areas of amyloid-enriched neuritic plaques. 
However, questions regarding the specificity of antibodies raised against the CB2 
receptor [23] made confirmation of these data necessary. Several groups successively 
provided data supporting the expression of CB2 receptors in microglial cells in the 
context of AD. Thus, Ramirez et al [24] reported that CB2 receptors were present in 
microglial cells in human AD samples. More recently, astudy in which the expression of 
CB2 receptors in the brains of two mouse models of AD was analyzed by 
immunohistochemistry and PET with the specific radiotracer [11C]A836339 confirmed 
this observation [25]. These authors also used human samples to complete their 
observations that described the presence of CB2 receptor in not only microglial cells but 
also astrocytes and neurons. Interestingly, CB2 receptor levels in microglia increased in 
AD, whereas those in neurons decreased in the disease. These data confirmed the value 
of CB2 receptors as diagnostic as well as putative therapeutic targets in AD and 
provided evidence for the expression of CB2 receptors in neurons, a matter of intense 
controversy. Another recent in vivo study found a decrease in CB2 receptor availability 




radiotracer used toward CB1 receptor and CB2 receptor [26]. Finally, by using a newly 
developed reporter mouse model, we have recently corroborated the selective 
expression of CB2 receptor in plaque-associated microglial cells in the 5xFAD mouse 
model of amyloidosis [27]. 
Few data are currently available regarding the levels of endocannabinoids and the 
functional status of their regulatory enzymes in AD. The metabolism of 2-AG and AEA 
has been shown to be altered in AD, both in human samples as well as in mouse models 
of the disease, with conflicting results. Thus, although an increase in AEA and 2-AG 
levels in the 5xFAD model of AD has been reported [28], we were unable to find 
significant differences in the same animal model [29]. In addition, other authors have 
reported decreases in 2-AG levels in the AβPPswe/PS1∆E9 mouse model of AD [19]. 
Regarding human samples, a significant decrease in AEA levels and its precursor 
NArPE, but not 2-AG, in the cortical areas of postmortem brain samples has been 
reported [30]. Furthermore, this decrease was correlated with the patients’ performance 
in cognitive tests of psychomotor speed and linguistic ability but not with amyloid 
plaque density or tau hyperphosphorylation. These data may correlate with those in 
previous reports in which an induction of the expression of the AEA-degrading enzyme 
fatty acid amide hydrolase (FAAH) was found in AD samples [22]. In this study, we 
observed an increase in FAAH immunoreactivity in hypertrophied astrocytes located 
around the foci of neuroinflammation, such as amyloid plaques. This increase was 
paralleled by a significant augment in FAAH enzymatic activity in samples obtained by 
microdissection of amyloid plaques. Finally, Mulder et al [31] used human AD samples 
to obtain data indicative of an enhanced endocannabinoid signaling, involving mainly 2-




loss of monoacylglycerol lipase (MAGL) enzymatic activity owing to impairment in its 
recruitment to biological membranes.  
Perhaps more difficult to interpret is data obtained from peripheral samples. The 
analysis of blood plasma revealed no changes in any of the endocannabinoids 
considered, and their levels showed no correlation with cognitive performance in 
healthy individuals at risk of AD [32]. Other authors, however, have found a significant 
increase in 2-AG and the AEA analog N-palmitoyl-ethanolamide levels in the blood 
plasma of patients with AD [33], and this could reflect a putative protective mechanism 
in the development of the disease. Interestingly, another report showed that an increase 
in FAAH mRNA and protein in peripheral blood mononuclear cells of patients with AD 
was linked to a decrease in the methylation state of the FAAH gene promoter region 
[34], thus suggesting a facilitation in gene expression. Inhibition of FAAH activity may 
render positive anti-inflammatory effects in the context of AD. 
 
2.2. Preclinical evidence for the therapeutic potential of cannabinoids in Alzheimer’s 
disease  
2.2.1. Cannabinoids and Aβ processing 
A neuroprotective role for cannabinoids against Aβ has been demonstrated in several in 
vitro and in vivo studies. The administration of endocannabinoids such as AEA, 2-AG, 
and noladin ether, or the supply of endocannabinoid reuptake inhibitors, increased the 
viability of neurons in culture exposed to different toxic Aβ species [35][36][37][38]. 
Similarly, exposure to cannabidiol (CBD), possibly the most atypical cannabinoid from 
a mechanistic perspective [38][39]; the synthetic CB1 receptor agonist ACEA [40]; the 
CB2 receptor selective agonists JWH-015 and JWH-133; or the mixed CB1/CB2 receptor 




toxicity in vitro. Neuroprotection against Aβ deleterious effects might underlie memory 
improvement observed after treatment with certain cannabinoids in animal models of 
AD. Either the elevation of endocannabinoid levels [42] or the administration of 
synthetic selective CB1 or CB2 receptor agonists [43][44][45], or nonspecific CB1 or 
CB2 receptor agonists [24][46][47] or CBD [46], reduced memory impairment in Aβ-
injected rodents. Moreover, chronic treatment with ACEA [40], JWH-133 [48][49], 
WIN55,212-2 [48], CBD [50][51], or with a combination of ∆9-THC and CBD [52][53] 
reduced the cognitive impairment in two different transgenic mouse models of AD.  
Multiple mechanisms might participate in neuroprotection against Aβ mediated by 
cannabinoid compounds, acting in parallel or interacting within them. Apart from the 
capacity of cannabinoids to indirectly mitigate the harmful effects of Aβ (i.e., 
inflammation and oxidative stress), which are discussed in the next sections, a direct 
effect of cannabinoids on Aβ processing has also been reported. ∆9-THC directly 
interacts with Aβ, thereby inhibiting its aggregation [41], and CBD induces the amyloid 
precursor protein (APP) ubiquitination and the consequent decrease in Aβ production 
through the activation of PPARγ [54]. 
CB2 receptor agonists facilitate Aβ clearance by stimulating the phagocytic activity of 
macrophages [55][45] and by favoring Aβ transport through the choroid plexus [48]. 
Similar Aβ clearance across the blood–brain barrier (BBB) was also demonstrated for 2-
AG, a synthetic CB1/CB2 receptor agonist, and MAGL but not for FAAH inhibitors in 
in vitro and in vivo BBB models [56]. The reduction in Aβ levels observed in AD 
mouse models chronically treated with CB2 or CB1/CB2 receptor agonists [48][28][57] 
and MAGL inhibitors [28][58] could be explained by the facilitation of Aβ clearance. In 
line with these observations, the genetic deletion of CB2 receptors altered the Aβ levels 




on Aβ production remains a matter of debate. Whereas some authors reported that 
specific agonists of this receptor did not alter the Aβ production, aggregation, or 
clearance in two different transgenic AD models [40][62], others provided evidence 
about a crosstalk between CB1 receptors and APP. On one hand, deletion of these 
receptors resulted in reduced APP protein levels and Aβ plaque deposition in APP23 
transgenic mice [63] but not in APP/PS1 mice [64]. Furthermore, APP overexpression 
altered membrane localization and inhibitory signaling activity of CB1 receptors in the 
hippocampus of Tg2576 mice [65]. On the other hand, the combination of ∆9-THC and 
CBD, but not each cannabinoid individually, resulted in a reduction in soluble Aβ42 
levels, the most toxic form of the Aβ peptide. This activity was CB2 receptor 
independent and might be achieved by facilitation of Aβ42 deposition in plaques to 
decrease its toxicity [52][61]. 
 
2.2.2. Effects of cannabinoids on tau hyperphosphorylation 
Cannabinoids are able to modulate tau hyperphosphorylation, another pathological 
hallmark of AD. Pioneering studies performed in Aβ-stimulated PC12 neuronal-like 
cells demonstrated that CBD, ACEA, and WIN 55,212-2 inhibited tau 
hyperphosphorylation by reducing the active form of glycogen synthase kinase 3β 
(GSK3β) by direct activation of CB1 receptor [66][67]. In agreement with these studies, 
a significant reduction in hyperphosphorylated tau levels was reported in the area 
surrounding Aβ plaques after chronic treatment with ACEA in the APP/PS1 mice [40], 
likely through the reduction in GSK3β activity as suggested in other studies [41]. 
Moreover, the same authors revealed a reduction in the activity of different tau kinases 
in APP/PS1 mice chronically treated with a specific CB2 receptor agonist, lowering tau 




deletion of CB2 receptors did not modify tau hyperphosphorylation in dystrophic 
neurites associated with Aβ plaques in the APP/PS1 mouse [61], although total tau 
levels were significantly decreased in a different AD mouse model lacking CB2 
receptors [59]. According to the hypothesis that suggests a role for cannabinoids in tau 
phosphorylation, a combination of ∆9-THC and CBD natural extracts reduced the 
formation of neurofibrillary tangles in parkin null, human tau overexpressing (PK-/-
/TauVLW) mice, a model of complex frontotemporal dementia (FTD), parkinsonism, 
and lower motor neuron disease [70]. 
 
2.2.3. Anti-inflammatory effects of cannabinoids 
It is currently accepted that the activation of the ECS is part of a neuroprotective 
response against different types of brain injury, including the appearance of neuritic 
plaques. The involvement of the ECS is partially based on its anti-inflammatory 
properties derived of the activation of CB1 and CB2 receptors [24][48] and also of 
PPARγ receptors [47][71] by endogenous ligands as well as by phyto and synthetic 
cannabinoids. As mentioned before, CB2 receptors are upregulated in microglial cells in 
AD, thus suggesting a role for them in the neuroinflammatory process triggered by 
amyloid deposition. This role has been described in studies performed both in vivo and 
in vitro, thus confirming the anti-inflammatory effects associated with CB2 activation 
(reviewed in [72][73]). Interestingly, these effects are accompanied by improvements in 
behavioral performance and also by decreased deposition of amyloid plaques, probably 
owing to a CB2-mediated decrease in cytokine secretion and enhancement of amyloid 
removal by increased phagocytosis. 
However, recent studies suggest that the contribution of this receptor type to AD 




complex than initially expected. Thus, the neuroprotective effect of an MAGL inhibitor 
in APP transgenic mice was independent of CB2 receptors [74]. Similar results were 
obtained in APP/PS1 mice treated with a combination of ∆9-THC and CBD [61]. These 
results are in agreement with those suggesting a limited role for CB2 receptors in the 
progression of AD-like pathology in 5xFAD [75][27] or APP/PS1 mice [61]. 
One of the most promising approaches for neuroprotection is the indirect enhancement 
of endocannabinoid levels through the inhibition of MAGL and FAAH [28][29] 
[58][75][74]. Both the pharmacological blockade of MAGL with JZL184 and its genetic 
inactivation improved behavior, decreased the density of amyloid plaques, and reduced 
astro- and microgliosis and the production of inflammatory cytokines [58][75]. 
Interestingly, none of these effects were prevented by CB1 receptor or CB2 receptor 
antagonists but were mediated primarily by alterations in arachidonic acid and/or 
prostaglandin signaling. As mentioned above, degradation of 2-AG by MAGL has been 
proposed as a novel pathway for prostaglandin synthesis and a new target to suppress 
neuroinflammation [76]. 
Evidence suggests a beneficial effect of FAAH inhibition in animal models of age-
related neuroinflammation [29][77]. Murphy et al [77] demonstrated that the selective 
FAAH inhibitor URB597 reversed the age-linked inflammation in terms of cytokine 
expression and preserved hippocampal long-term potentiation in aged rats. 
Pharmacological inhibition of FAAH with URB597 had a limited effect in 5xFAD mice 
in terms of cytokine expression and behavior, which contrasted with the significant 
changes observed after genetic inhibition [29]. Interestingly, our data are suggestive of a 
putative shift in the ECS neurotransmission from a CB1 receptor-mediated anti-
inflammatory action to a pro-inflammatory one, in the context of AD and triggered by a 




beneficial, as mice showed improvements in memory and decreased amyloid deposition. 
It is still unknown whether these changes involve, for instance, preservation of neuronal 
morphology in the hippocampus. In any case, it seems to be currently accepted that 
inhibiting FAAH activity may render positive effects, and in fact, mixed inhibitors for 
FAAH and other enzymes, i.e., acetylcholinesterase (AChE) or butyrylcholinesterase, 
are under study to be used as potential therapeutic tools for AD [78][79]. 
 
2.2.4. Other effects of cannabinoids 
Many studies report different effects of cannabinoids with potential interest for AD. 
Alterations in the components of the respiratory chain located in the inner mitochondrial 
membrane that lead to the production of excessive ROS are described in brains affected 
by AD [80], with subsequent oxidative damage of certain macromolecules that 
jeopardizes their functionality. Compounds that are able to counteract free radical 
damage are then assumed to confer neuroprotection, which bestows them potential 
utility against AD [81]. Among the antioxidant compounds tested in AD models, a few 
cannabinoids have been included. CBD was the first one to be evaluated. CBD 
prevented ROS production and lipid peroxidation in PC12 neuronal-like cells exposed 
to Aβ, reduced apoptosis, and counteracted the Aβ-induced increase in intracellular 
calcium concentration [39]. CBD also reduced the levels of nitric oxide (NO) and the 
expression of the inducible NO synthase (iNOS) [67][82]. Mechanisms of action of 
CBD have been classically assigned to cannabinoid receptor-independent antioxidant 
properties, a fact derived from its particular chemical structure having two hydroxyl 
groups. Recent evidence relates this potential to novel nonendocannabinoid signaling 
mechanisms, e.g., PPAR-γ, Nrf-2 signaling, and adenosine signaling [68]. Recent 




CB2 [83] receptors. Although it is unlikely that this capability may underlie its 
antiexcitotoxic, anti-inflammatory, and neuroprotective properties, which are related to 
elevated rather than reduced CB1 and CB2 receptor signaling, these properties may be 
supported by the ability of CBD to increase the activity of mitochondrial complexes in a 
hippocampal cell line [84] in different structures related to AD in the rat brain [85] and 
to rescue memory deficits in rats [86]. However, studies using the mitochondrial 
fraction from the pig brain cortex claim that CBD inhibits the activity of the respiratory 
chain [87][88].  
Cannabinoids also exhibited antioxidant properties in in vivo models of AD. Thus, The 
selective CB2 receptor agonist JWH-133 reduced hydroxynonenal adducts, derived from 
lipid peroxidation, and enhanced the levels of the superoxide dismutases 1 and 2 in the 
area surrounding Aβ plaques in APP/PS1 mice, thus demonstrating a role for CB2 
receptors in promoting responses against oxidative stress and reducing its harmful 
consequences [49]. The combination of ∆9-THC and CBD also resulted in a reduction 
of free radicals in a mouse model of tauopathy [70] and in the augmentation of the 
levels of thioredoxin 2 protein, a member of the mitochondrial antioxidant system 
responsible for the clearance of reactive intermediates and the repair of proteins with 
oxidative damage [52]. 
Certain cannabinoids are known to act on the same targets compared to the current 
medications for AD, i.e., AChE inhibitors and noncompetitive antagonists of the N-
methyl D-aspartate (NMDA) receptor. ∆9-THC competitively inhibits AChE increasing 
acetylcholine availability and prevents AChE-induced Aβ aggregation [89]. CB2 
receptor agonists exhibit inhibitory effects on butyrylcholinesterase [90]. The synthetic 
cannabinoid HU-211 inhibits NMDA receptors, thereby protecting cells from 




against excitotoxicity by inhibiting presynaptic glutamate release [94] and excessive 
calcium release [95][96][97]. In agreement with these observations, the combination of 
∆
9-THC and CBD modulated the levels of certain glutamatergic and GABAergic 
receptors in the cortex of aged APP/PS1 mice, thus suggesting an attempt of these 
natural cannabinoids to reduce the imbalance of excitatory versus inhibitory neural 
activity occurring in AD [53]. 
Additional beneficial effects of cannabinoids in AD include their capacity to prevent 
Aβ-mediated lysosomal destabilization in cultured neurons, thereby reducing the 
apoptotic signaling [98]; to promote neurogenesis in response to Aβ insult [82][99]; to 
normalize the levels of the presynaptic SNAP25 protein involved in aberrant neuritic 
sprouting in brain areas affected by Aβ [49]; and to induce autophagy facilitating the 
degradation of aberrant cellular components [70]. Moreover, a recent study revealed 
that the CB1/CB2 mixed agonist WIN 55,212-2 and the CB2 selective agonist JWH-133 
ameliorated the vascular dysfunction in a transgenic model of AD [100]. In addition, a 
role for CB2 agonists in stimulating brain glucose uptake was also described in the same 
animal model [101]. 
 
2.3. Therapeutic implications for a cannabinoid-based therapy for Alzheimer’s 
disease: clinical evidence and future perspectives 
Considering the complexity of the pathological mechanisms involved in the progression 
of AD, compounds such as cannabinoids targeting in parallel several processes that play 
key roles in AD could offer a more promising therapeutic profile than treatments 
targeting a single causal or modifying factor. However, as described above, the potential 
therapeutic utility of cannabinoids in AD is mainly based on the evidence obtained 




from the bench to the bed. Nevertheless, it is worth noting that the limited clinical 
information on the use of cannabinoids in patients with dementia also suggests some 
beneficial effects. Clinical trials in patients with AD at advanced stages who received an 
analog of ∆9-THC (nabilone or dronabinol) for several weeks showed a significant 
reduction in agitation and aggression refractory to antipsychotics and anxiolytics, 
together with weight gain in individuals previously rejecting food, although no 
reduction in other neuropsychiatric symptoms was observed. Equally important is the 
almost total absence of side effects observed during treatment with ∆9-THC in these 
patients, and beyond a certain euphoria, drowsiness or fatigue 
[102][103][104][105][106][107]. Despite the limited number of subjects included in the 
trials and the lack of assessment of cognitive parameters and markers of 
neurodegeneration, which limits drawing definitive conclusions about the effectiveness 
of ∆9-THC in the treatment of dementia [108], the available information derived from 
these studies is relevant and, together with the extensive basic evidence, provides 
encouragement for conducting controlled clinical trials geared to clarifying the 
therapeutic potential of cannabinoids in AD. 
 
3. Cannabinoid pharmacology in Parkinson’s disease 
PD, the second most common neurodegenerative disease, is a motor disorder affecting 
1-2% of the population aged more than 65 years, with an incidence that increases with 
age [109]. The classic motor symptoms rigidity, bradykinesia, and tremor, are caused by 
the striatal dopamine deficit generated by the specific loss of dopaminergic neurons in 
the substantia nigra pars compacta (SNpc). The SNpc, the striatum (caudate nucleus 
and putamen), the globus pallidus (internal and external segments, GPi and GPe, 




that are part of the basal ganglia, a group of brain nuclei involved in the control of 
movement whose activity is primarily affected in PD. The most effective treatment for 
PD is levodopa (L-dopa), a dopamine replacement therapy that was identified 50 years 
ago [110]. However, as the disease progresses and more neurons are lost, the efficacy of 
L-dopa decreases and patients experience motor fluctuations and abnormal involuntary 
movements known as L-dopa-induced dyskinesia (LID) [111]. The development of new 
nondopaminergic drugs capable of attenuating motor symptoms without producing 
dyskinesia is necessary. Ultimately, disease-modifying treatments are needed to stop the 
neurodegenerative process. On the basis of the cellular location of cannabinoid targets 
and the neuroprotective activities described for cannabinoids, they represent an 
interesting therapeutic approach for PD. 
Different aspects of the disease can be reproduced in experimental animals. Models 
based on classic neurotoxins, such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP), 6-hydroxydopamine (6-OHDA), rotenone, paraquat, or lipopolysaccharide 
(LPS), reproduce the loss of dopaminergic neurons and the motor impairment, thus 
representing a late-stage model of the disease. Transgenic or knockout genetic models 
simulate better the pathogenic mechanisms of PD, but their pathological and behavioral 
phenotype is often quite different from that of the human condition. Similar strategies 
are used to generate in vitro cellular models [112]. 
3.1. The Endocannabinoid System in Parkinson’s disease 
In agreement with the effect of cannabimimetic drugs on motor activity, different 
elements of the ECS are abundant in the basal ganglia [113]. The high density of CB1 
receptor immunoreactivity in these nuclei, except for dopaminergic neurons in the SNpc, 
supports a role for these receptors in the regulation of basal ganglia physiology and 




glutamatergic terminals within basal ganglia leads to presynaptic inhibition of 
neurotransmitter release [115]. In the striatum, the ECS interacts closely with the 
dopaminergic system. Activation of postsynaptic dopamine type 2 receptors stimulates 
AEA release that activates CB1 receptors in a retrograde manner to downregulate 
glutamate neurotransmission [116][117]. Although dopaminergic neurons lack CB1 
receptors, they can be activated in a CB1 receptor-dependent manner by reducing their 
GABAergic input, thereby favoring dopamine release [118][119]. Cannabinoid 
receptors and their endogenous ligands are modulated in animal models and patients 
with PD. CB1 receptors showed no differential expression in the striatum of 6-OHDA-
lesioned rats, but a significant increase in the receptor levels was observed in animals 
treated with L-dopa [120][121]. A transient increase in CB1 receptor transcripts in the 
striatum of the 6-OHDA rats, which was not accompanied by changes in [3H]WIN-
55,212-2 binding or [35S]GTPγS stimulation, was described in the striatum, GPe, and 
SNpr [120][122][123]. [3H]CP-55,940 binding and [3H]WIN-55,212-2 activation of 
[35S]GTPγS were upregulated in MPTP-lesioned marmosets and returned to control 
levels upon L-dopa treatment [124]. Interestingly, an increase in CB1 receptor 
expression was detected in the basal ganglia of parkinsonian monkeys treated with L-
dopa exclusively during the active phase of dyskinesia, CB1 receptor transcripts 
returned to control levels when MPTP monkeys were not under the effect of L-dopa 
[125]. Not only receptor activation but also endocannabinoid levels are altered in 
experimental models of PD. The levels of AEA, but not 2-AG, were increased in the 
striatum of the 6-OHDA rat [126]. MPTP-lesioned marmosets showed elevated levels 
of AEA in the striatum and GPe, and these levels decreased to control levels with L-
dopa therapy. 2-AG was increased in the striatum and substantia nigra (SN) but 




therapy but persisted when LID was present [127]. Changes in the expression levels of 
AEA synthesizing/degrading enzymes in the GPe of MPTP monkeys suggest a role for 
this endocannabinoid as a compensatory mechanism to counteract the dopamine deficit 
[125]. Changes in the expression of 2-AG synthesizing/degrading enzymes during the 
active phase of dyskinesia suggest that this endocannabinoid may play a role in LID 
[125]. 
Studies carried out with human samples from patients with PD are difficult to interpret 
because patients are under L-dopa treatment, and most of them do not mention the 
presence of LID. Therefore, it is not possible to determine whether the observed 
changes are due to the disease itself, due to the dyskinetic status, or due to the chronic 
dopaminergic therapy. Analysis of CB1 receptor transcripts in the postmortem tissue 
from L-dopa-treated patients with PD showed a downregulation restricted to the 
anterior-dorsal region of the putamen and to the GPe, thus suggesting that their 
expression might be modulated heterogeneously in the putamen [128]. A similar study 
showed an upregulation of CB1 receptor transcripts in the putamen [129]. The small 
piece of tissue comprising different regions of the putamen might account for the 
different observations. The binding of [3H]CP-55,940 was increased in the caudate 
nucleus and putamen, and the stimulation of [35S]GTPγS by [3H]WIN-55,212-2 was 
high in the caudate nucleus, putamen, GPe, and SN of patients with PD [124]. An 
interesting study measured CB1 receptor binding in vivo by PET in different groups of 
patients with PD using the selective radioligand [18F]MK-9470 [130]. An increase in 
CB1 receptor availability was displayed in the putamen and a decrease in the SN of 
patients with PD with regard to controls. In this case, no regional differences were 
detected between patients with or without LID [130]. Analysis of AEA levels in the 




and those undergoing a complete L-dopa washout presented higher AEA levels, and 
these levels were restored to control levels in patients under chronic dopaminergic 
therapy [131]. Therefore, data obtained from patients with PD and animal models point 
toward profound rearrangements of the ECS in the basal ganglia after dopamine 
depletion and with dopamine replacement therapy.  
The presence of CB2 receptors has been demonstrated in activated microglia of the 
diseased brain [132], thus suggesting that CB2 receptors are upregulated as part of the 
activation process. Albeit some limitations, there is evidence of CB2 receptor expression 
in striatal fibers and in the SN of rats [133] and in the GPe and GPi of primates 
[134][135]. There is no consensus regarding the cellular localization of CB2 receptors in 
the human brain of patients with PD. A predominant expression of CB2 receptors has 
been reported in activated microglia and dopaminergic neurons of SN [136][137]. 
However, Navarrete et al. (2018) reported a major localization of CB2 receptors in 
activated astrocytes [129]. 
Neuroinflammation is a classical neuropathological hallmark of patients with PD 
[139][140] and of animal models of the disease. Intrastriatal administration of LPS, 6-
OHDA, or rotenone induced an increase in CB2 receptor mRNA levels that correlated 
with microglial cell activation [141][142]. In the acute MPTP mouse model, CB2 
receptor was upregulated in microglial cells of the midbrain but not in the striatum 
[143]. Similar to these results, CB2 receptor transcripts were upregulated in SN and 
downregulated in the putamen of parkinsonian patients [129].  
These data highlight the potential role played by the ECS in PD pathophysiology and 
LID and provide an excellent opportunity to develop new therapeutic strategies directed 
specifically toward different aspects of the disease. Neuronal cannabinoid receptors 




might influence motor and nonmotor symptoms of PD or counteract LID. The ability of 
CB2 receptors to modulate the immune response places them as an interesting 
therapeutic target for neuroprotection. 
 
3.2. Preclinical evidence for the therapeutic potential of cannabinoids in PD 
Animal studies suggest that cannabinoids improve motor symptoms of PD and LID and 
that they exert neuroprotective effects through cannabinoid receptor-dependent and -
independent mechanisms. Because blockade of CB1 receptors facilitates dopamine type 
2 receptor-mediated facilitation of movement [116], CB1 receptor antagonists would 
enhance dopaminergic transmission. Furthermore, one of the classical effects of direct 
activation of CB1 receptors in rodents is the cannabinoid tetrad, including catalepsy and 
hypolocomotion [144], which supports the use of CB1 receptor antagonists for akinesia. 
With regard to this, motor behavior in different 6-OHDA rat models was improved by 
the CB1 receptor antagonists rimonabant, AM251, and the phytocannabinoid ∆
9-
tetrahydrocannabivarin (∆9-THCV) at low doses [145][146][147]. Rimonabant as 
monotherapy ameliorated parkinsonian symptoms in MPTP primates and reduced LID 
without compromising L-dopa efficacy [127], although a lack of beneficial effect has 
also been reported in this animal model [148]. Paradoxically, CB1 receptor agonists 
improve motor impairment. Administration of either the nonselective cannabinoid 
receptor agonist CP 55,940 or AM404 to enhance AEA availability into the denervated 
striatum of 6-OHDA rats had anti-parkinsonian properties [149][150]. ∆9-THC had anti-
parkinsonian properties in MPTP-lesioned marmosets, although it induced side effects 
[151]. From a theoretical perspective, the anti-parkinsonian effect of both CB1 receptor 
activation and blockade could be explained depending on which nuclei of the basal 




ECS in the basal ganglia under parkinsonian conditions, dose, gender, trial design, or 
the extent of the dopaminergic lesion might explain the different efficacy of agonists or 
antagonists [145][146][151]. The specific localization of CB1 receptors at glutamatergic 
or GABAergic terminals of neurons in different basal ganglia nuclei [153] and alteration 
of these pools of receptors under pathological conditions might account for such effects. 
Promising data arise from pharmacological studies targeting CB2 receptors. In the 6-
OHDA rat model, which has a lower inflammatory response than other PD models, a 
mild improvement in dopamine levels was detected after the administration of the CB2 
receptor agonist HU-308 [154]. Treatment of the acute MPTP mouse model with WIN 
55,212-2 before the neurotoxin injection protected dopamine neurons from degeneration 
in a CB2 receptor-dependent manner, probably through the inhibition of microglial 
activation. In fact, all CB2 receptor
 knockout mice died after MPTP administration, thus 
suggesting that they are critical for protection against the neurotoxin [143]. Similar 
results were obtained with a lower dose of WIN 55,212-2 and with the CB2 receptor 
selective agonists JWH-133 and AM1241 [155][156]. Striatal LPS injection induced a 
mild dopaminergic neurodegeneration and a prominent proinflammatory response. The 
CB2 receptor selective agonist HU-308 and the CB2 receptor agonist activity of the 
phytocannabinoid ∆9-THCV protected dopaminergic neurons and decreased the 
expression of the microglial activation markers CD68 and iNOS in the striatum 
[137][147]. Interestingly, dopamine neurons in the CB2 receptor knockout mice showed 
a high vulnerability to LPS and a high degree of macrophage infiltration and astrogliosis 
in the SN [147][137]. In the rotenone rat model, pretreatment of rats with β-
caryophyllene, a phytocannabinoid and selective agonist of CB2 receptor, prevented 




Biological actions of endocannabinoids are terminated by enzymatic hydrolysis. In the 
CNS, the MAGL is the main 2-AG-inactivating enzyme and AEA is hydrolyzed by the 
FAAH [158][159]. Therefore, rather than direct stimulation of cannabinoid receptors 
with exogenous ligands, an interesting approach is to increase the levels of the 
endocannabinoids, 2-AG or AEA, by inhibiting their degradation. MAGL inhibition 
with JZL184 increased 2-AG levels in the brain, improved motor behavior, and exerted 
neuroprotective effects in the chronic MPTP mouse model [160]. In vitro studies 
showed that the neuroprotective effect of JZL184 was mediated by CB2 and not by CB1 
receptors [161]. By contrast, FAAH inhibition with URB597 increased AEA levels in 
the brain and improved motor behavior but lacked neuroprotective activity [162]. Both, 
CB1 and CB2 receptors were involved in the symptomatic relief exerted by URB597, 
thus suggesting that it was mediated by neuronal CB2 receptors probably through 
CB1/CB2 receptor heteromers [162]. The efficacy of dopamine type 2 receptor agonists 
to improve motor behavior was enhanced by the co-administration of URB597 [163]. 
Phytocannabinoids have cannabinoid receptor-independent anti-parkinsonian properties. 
∆
9-THC and CBD restored dopamine levels in the 6-OHDA rat model in a CB1 
receptor-independent manner [120], presumably by acting through the same 
mechanisms (e.g., PPAR-γ, Nrf-2 signaling, thus improving mitochondrial function), 
and these mechanisms have been described for AD in the previous subsection (see 
2.2.4.). However, a lack of neuroprotective activity was described for CBD in the 
chronic MPTP mouse model [164]. The phytocannabinoid ∆9-THCV, with its 
antioxidant properties and the ability to activate CB2 and to block CB1 receptors, 
presents an interesting pharmacological profile for PD. It protected dopaminergic 
neurons in the 6-OHDA and in the LPS mice models [147]. An interesting group of 




receptors involved in the control of neuroinflammatory responses [166]. AEA is among 
the lipids that are considered to be an endogenous ligand for PPARs [167]. Some 
quinone derivatives of cannabigerol (CBG) such as VCE-003.2 act as PPARγ activators 
and attenuate the loss of dopaminergic neurons in the LPS mouse model by decreasing 
the inflammatory response [168]. However, VCE-003.2 failed to protect dopaminergic 
neurons in the 6-OHDA mouse model, probably because of the poor inflammatory 
response of the model [168].  
 
3.3. Clinical evidence for the therapeutic potential of cannabinoids in PD and future 
perspectives. 
Clinical trials to test the beneficial effect of cannabinoids in different aspects of PD do 
not show consistent results. Nabilone, a nonselective CB1 receptor and CB2 receptor 
agonist, improved LID [169]. Oral administration of a cannabis extract to patients with 
PD in a randomized, placebo-controlled, crossover study concluded that it did not 
produce any pro- or anti-parkinsonian effect [170]. By contrast, an open-label 
observational study showed that smoked cannabis improved motor symptoms of PD 
such as bradykinesia, tremor, and rigidity and nonmotor symptoms of the disease such 
as sleep and pain [171]. However, a single dose of smoked marijuana failed to improve 
tremor, thus suggesting that the anxiolytic action might benefit some patients with 
tremor when anxiety is an important triggering factor [172]. A subjective improvement 
in motor symptoms, namely, bradykinesia, rigidity, and tremor, and alleviation of LID 
was reported in patients with PD who smoked cannabis [173]. However, a different 
study reported that the main benefit was observed in sleep rather than in motor 
symptoms [174]. A retrospective study collecting subjective impressions of patients 




treatment without major adverse effects [175]. The different outcome of studies using 
plant extracts could be related to the administration route because cannabinoids are 
lipid-soluble compounds; hence, oral administration results in lower peak 
concentrations in plasma than through inhalation. The ∆9-THC content and the ∆9-
THC:CBD ratio are other parameters to be considered. 
These results indicate that targeting the ECS might be useful in the treatment of PD 
symptoms or dyskinesias. Further clinical studies involving large samples of patients, 
placebo groups, appropriate molecular targets, and objective outcome measures are 
necessary to clarify the effectiveness of cannabinoid-based therapies.  
The potential role played by the ECS in PD provides an excellent opportunity to 
develop new therapeutic strategies aimed at different aspects of the disease. Although 
an enormous effort has been made in understanding the elements of the ECS, further 
studies are necessary to unravel the functional significance of the system under 
physiological and pathological conditions. The complex interplay between the main 
neurotransmitter systems in the basal ganglia and the modulatory role of the ECS, 
mainly through CB1 receptors, might provide the base for the development of 
nondopaminergic therapies or alleviation of LID. Among the different cannabinoid 
targets, stimulation of CB2 receptors, either directly or by increasing endogenous 
cannabinoids, might offer an interesting disease-modifying alternative and a 
nondopaminergic therapy for the disease.  
The inconsistent effect of some cannabinoid receptor ligands could be attributed to their 
functional selectivity to induce specific conformational changes in the receptors 
modulating different intracellular signaling pathways [176][177]. Furthermore, 
cannabinoid receptors can form heteromers with other G-protein-coupled receptors 




[178][179]. The use of CB1 receptor antagonists has been successfully investigated in 
preclinical models, but the only clinical trial using rimonabant for the hypokinetic 
symptoms in PD failed [180]. However, this trial recruited patients with PD who all 
responded well to L-dopa, and it is possible that rimonabant could be a better option for 
those patients who do not respond to classic dopaminergic replacement therapy 
(approximately 30%). While an attempt to directly target CB1 receptors seems an 
improbable clinical approach for PD, manipulation of endogenous levels of AEA and 2-
AG or compounds targeting different receptors may be a promising strategy. Further 
research is needed to define multiple opportunities for manipulating this system in 
movement disorders. 
 
4. Cannabinoid pharmacology in Huntington’s disease 
The key clinical symptoms in HD are choreic movements, which are produced by the 
degeneration of striatal medium-sized spiny neurons projecting to the GPe and SN [181]. 
The disease is also accompanied by behavioral disturbances and dementia, which are 
caused by the deterioration of specific neurons located in cortical structures [182]. 
These two neuronal subpopulations are the most vulnerable cells affected in this genetic 
pathology and the first to deteriorate [181][182][183]. However, the disease may 
ultimately affects other neuronal subpopulations in different CNS structures such as the 
cerebellum [183]. From a molecular perspective, HD is an inherited disorder caused by 
mutations in the gene encoding the regulatory protein huntingtin. The mutation consists 
in an excessive number of CAG repeats in the first exon, and this leads to a 
polyglutamine trait in the amino terminal end, thus causing a variety of anomalies in its 
cellular function [184]. HD is the most prevalent polyglutamine disorder, which also 




neuropathological feature in HD is the formation of inclusions of the mutant huntingtin, 
with ubiquitin and other proteins. These inclusion bodies are located predominantly in 
the cell nucleus producing a transcriptional dysregulation of key genes like BDNF [186]. 
With lower frequency, huntingtin inclusions are also found in the cytosol and in the 
neurites, thereby pointing out the damage observed in mitochondria and cytoskeleton, 
respectively [184]. The disease can be recapitulated in laboratory animals, including 
predominantly mice (e.g., R6/1, R6/2, HD94, and YAC128) and also other vertebrates 
(e.g., zebrafish) or invertebrates (Drosophila and Caenorhabditis elegans) by means of 
transgenes containing the human mutant huntingtin, and also in cells transfected with 
these mutant forms. Additional models may be generated by intrastriatal or systemic 
administration of excitotoxins or mitochondrial toxins (e.g., inhibitors of mitochondrial 
complex II) (see [187] for a review on experimental models). Pharmacological therapies 
for patients with HD are extremely limited and circumscribed to the treatment of 
choreic movements. Currently, the only agent licensed is the inhibitor of the vesicular 
monoamine transporter-1 tetrabenazine (Xenazine) [188]. Some antioxidants, 
minocycline, histone deacetylase inhibitors, and unsaturated fatty acids have been or are 
being investigated at the clinical level [188][189]. Cannabinoids were included in the 
list of neuroprotective agents investigated for HD early in the 2000s [190], although 
they had already been investigated as symptom-relieving agents [191]. In both cases, 
the research reached the clinical scenario [192][193][194][195][196][197]. 
 
4.1. The endocannabinoid system in Huntington’s disease 
Numerous changes in the endocannabinoid elements, affecting mainly CB1 and CB2 
receptors and the hydrolyzing enzymes, have been described in brain samples from 




from patients with HD [198] and in different transgenic animal models 
[199][200][201][202][203] was the early defects in striatal CB1 receptor signaling with 
a progressive loss of these receptors, which was evident even before neuronal death and 
the occurrence of choreic symptoms. An early stimulation of the CB1 receptors located 
in striatal projecting neurons dampened their impairment, thus improving their capacity 
to inhibit the excitotoxic events that initiate the damage and to regulate growth factor 
generation that promotes striatal neuron survival [204]. 
Downregulation of CB1 receptors might be caused by a loss of function of the mutant 
huntingtin in its capacity to sequestrate the gene silencing factor REST to the cytoplasm, 
which facilitates its translocation to the nucleus and the inhibition of different genes 
including BDNF and Cnr1 [205]. Other studies described equivalent effects exerted 
through the inhibition of the ability of the mutant huntingtin to regulate other 
transcriptional modulators such as CREB-binding protein/CREB or NFκB-p65/Re1A 
acting at the promoter of the CB1 receptor gene [206]. Despite the relationship between 
the reduction in CB1 receptors and the mutant huntingtin, an early impairment in CB1 
receptor coupling to G proteins was observed days before the onset of the striatal 
degeneration in an experimental model generated by neurotoxin administration, the rat 
lesioned with the irreversible mitochondrial complex II inhibitor 3-nitropropionate 
[207]. Further studies conducted in R6/2 transgenic mice described that, the loss of CB1 
receptors within the basal ganglia was evident in striatal projecting neurons, but it was 
preserved in corticostriatal neurons. The relationship between CB1 receptor expression 
and neuronal vulnerability suggests that this receptor pool constitutes a promising target 
for neuroprotective therapeutic strategies [208][209]. These observations modified the 
initial idea that the potential benefits of CB1 receptor activation are restricted at early 




intermediate and advanced stages of the neurodegenerative process [210][209]. 
Although this question needs to be investigated, a recent study has demonstrated that 
the activation of corticostriatal CB1 receptors protects striatal neurons projecting to the 
SN, but not those projecting to the GPe, against different insults [211]. 
The expression of CB2 receptors is also altered in patients with HD and animal models. 
In rats lesioned with malonate, a reversible complex II inhibitor applied directly into the 
striatum [212]; genetic mouse models [213][214]; and postmortem tissue from patients 
with HD [213], CB2 receptors were overexpressed in activated astrocytes and microglial 
cells recruited to the lesioned site [212][213][214]. One study conducted with human 
HD tissue samples failed to detect CB2 receptor expression in astrocytes and microglial 
cells but located this receptor in endothelial cells [215]. Alteration in cannabinoid 
receptors in HD shows consistent results among different experimental models, 
neurotoxin-based or transgenic model, and human samples. The deficit of CB1 receptors 
clearly represents an alteration that contributes to HD progression by promoting 
excitotoxic damage and growth factor deficiency. CB2 receptor expression increases 
during the progression of the disease, and it appears to be more of an endogenous 
protective response. 
Endocannabinoid levels were also markedly reduced in the brain in experimental 
models of HD [216][217]. By contrast, the R6/2 transgenic mouse model presented an 
increase in FAAH levels [205][218]. Recent studies in patients with HD identified an 
increase in endocannabinoid levels in the blood due to a reduction in FAAH activity 
[219], thus suggesting that changes related to FAAH levels and activity in human 
patients may be different from those in animal models. A reduction in the level of this 
enzyme in patients with HD may be interpreted as an endogenous protective response to 




be part of the pathogenesis supporting the interest of exploring the possibilities of 
therapies based on FAAH inhibition for HD [205][218]. 
 
4.2. Preclinical evidence for the therapeutic potential of cannabinoids in 
Huntington’s disease 
The positive results obtained in a broad spectrum of animal models of HD confirmed 
the benefits of specific cannabinoids against different cytotoxic stimuli reproduced in 
the experimental models [220][14]. The cannabinoid receptor agonist WIN 55,212,2 
protected striatal neurons in a rat model that relies on quinolinate-induced excitotoxic 
damage [204]. CB1 receptor activation with ∆
9-THC in the genetic model of the disease 
R6/2 mice attenuated striatal neuron loss, whereas striatal degeneration was aggravated 
in R6/2 mice with a genetic deficiency in CB1 receptors [205]. The genetic rescue of 
CB1 receptors using viral approaches recovered striatal synapses, although it was 
ineffective for the motor impairment [221]. The genetic ablation of the CB1 receptor in 
other HD murine transgenic model or following 3-nitropropionate intoxication yielded 
equivalent results [222]. 
Cannabinoids that activate the CB2 receptors selectively are also effective in HD, acting 
preferentially on inflammatory events and microglial activation in rats lesioned with 
malonate [212] in R6/2 mice [213] and following the excitotoxic lesion with quinolinate 
in mice [213]. The treatment of R6/1 transgenic mice with low doses of the nonselective 
synthetic agonist WIN 55,212-2 prevented the development of motor deficits and 
preserved striatal projecting neurons, although the study did not specified whether these 
effects were CB1 and/or CB2 receptor dependent [223]. However, administration of the 
nonselective cannabinoid agonists either HU-210 or ∆9-THC to R6/1 mice lacked 




impairment but improved CB1 striatal expression [224]. Differences in doses or agonists 
might account for such differences. 
Antioxidant nonpsychoactive phytocannabinoids CBD and CBG have also been 
investigated in experimental models of HD, although their effects are independent of 
CB1 and CB2 receptors. CBD was neuroprotective in rats intoxicated with 3-
nitropropionate, a model characterized by mitochondrial damage, oxidative stress, and 
calpain activation [225]. By contrast, it was inactive in malonate-lesioned rats, a HD 
model with a pro-inflammatory component [212]. CBG was neuroprotective in the R6/2 
and the 3-nitropropionate-lesioned mice [226]. The effect of CBD and CBG might be 
mediated by the activation of nonendocannabinoid targets such as PPARs or by the 
other mechanisms indicated before for CBD (see subsection 2.2.4). The quinone 
derivative of CBG VCE-003.2, which activates PPARγ improved neuronal survival 
against the neurotoxicity caused by the mutant huntingtin and quinolinate in vitro, and 
against quinolinate and 3-nitropropionate in vivo [227]. Based on these broad-spectrum 
effects of cannabinoids in HD in experimental models, a combination of CBD with ∆9-
THC, as in the cannabinoid-based medicine Sativex, was studied in animal models of 
HD [210]. This combination preserved striatal neurons in the neurotoxin-induced 
models, the malonate-lesioned mouse [228], and the 3-nitropropionate-lesioned rat 
[229]. In R6/2 mice, only ∆9-THC in the form of botanical extract showed a beneficial 
effect [230]. 
 
4.3. Clinical evidence for the therapeutic potential of cannabinoids in Huntington’s 
disease and future perspectives 
The first clinical trials with cannabinoids in HD were conducted in the 1990s and 




improve choreic movements. However, an aggravation of these movements was 
reported [192][231][193]. Nabilone was beneficial on chorea and behavioral 
disturbances in a case report study [194] and in a pilot clinical study [195]. Recently, a 
clinical study investigated the effect of different cannabinoid formulations, Sativex®, 
nabilone, or dronabinol on dystonia, a frequent symptom in HD [232], and patients 
experienced motor improvements mainly in dystonia and presented less irritability and 
apathy [197]. These clinical studies conducted with cannabinoids were focused on 
symptom relief. 
With regard to neuroprotectant effects, the positive results obtained in experimental 
animals with the combination of CBD and ∆9-THC supported to test whether Sativex® 
may serve as a disease-modifying therapy for patients with HD [196]. The trial was 
conducted in Spain and was the first trial designed to test a neuroprotective strategy. 
Although Sativex® was safe and well-tolerated in patients with HD, unfortunately, it 
failed to provide evidence that it may slow down disease progression in HD [196]. Such 
failure may be related to the relatively short time, 12 weeks, for the active treatment and 
an unexpected prolonged placebo effect [196], thus suggesting the need for additional 
clinical testing using longer periods of treatments. 
Therefore, the major challenges for cannabinoid-based therapies in HD are to find the 
appropriate cannabinoid formulations and to implement clinical trial designs to correlate 
the benefits observed in the preclinical models with a positive effect in patients with HD. 
A formulation with a single cannabinoid with a broad-spectrum profile might render a 
positive outcome, but a formulation based on the combination of cannabinoids with 
different activities would be better. In fact, this was the reason to select Sativex [196]. 




treatment versus placebo would be necessary to reveal a neuroprotective effect in 
patients with HD treated with Sativex or similar preparations [196]. 
 
5. Cannabinoid pharmacology in Amyotrophic Lateral Sclerosis 
ALS is a progressive neurodegenerative disease predominantly affecting the upper and 
lower motor neurons leading to muscle denervation, atrophy, and paralysis [233]. The 
most abundant form of the disease is sporadic [234]. Approximately, 20% of patients 
present a hereditary form of ALS, which is associated with mutations in genes encoding 
for the key antioxidant enzyme superoxide dismutase-1 (SOD-1), and the proteins 
involved in pre-mRNA splicing, transport, and stability of TAR-DNA-binding protein-
43 (TDP-43) or FUS (fused in sarcoma) protein [233][235]. More recently, a CCGGGG 
hexanucleotide expansion was described in the C9orf72 gene, which represents most of 
the cases of familial ALS [236]. It encodes a protein involved in intracellular trafficking 
in neurons and other cell functions not completely understood [237]. Familial and 
sporadic forms of ALS are clinically and histopathologically indistinguishable, sharing 
pathogenic events and therapeutic intervention. In the case of some ALS-related genes, 
TARDBP (encoding TDP-43), FUS, or C9orf72, the disease can be accompanied by 
features of FTD, which supports the idea that, rather than being one disorder, ALS 
belongs to a broad spectrum of disorders ranging from motor to cognitive deficits [238]. 
As in other neurodegenerative disorders, the damage of upper and lower motor neurons 
occurs by the combination of excitotoxicity, chronic inflammation, oxidative stress, 
protein aggregation, and other cytotoxic events [239][240][235]. A characteristic feature 
in ALS pathogenesis is the extreme vulnerability of the axonal transport of proteins or 
cell organelles owing to their excessive axonal length of motor neurons [241]. 




overexpressing mutated forms of the different ALS-related genes (e.g., SOD-1, 
TARDBP, and C9orf72) [242]. The disease still lacks an effective treatment for 
symptoms and/or disease progression. For a long time, the antiexcitotoxic agent riluzole 
(Rilutek®) was the only approved drug [243]. More recently, the antioxidant agent 
edavarone (Radicava®) and the tyrosine kinase inhibitor masitinib [244] have been 
approved (or designed as orphan drugs) for the treatment of patients with ALS. Solid 
evidence derived from studies describing the changes in specific elements of the ECS in 
the spinal cord, brainstem, and motor cortex, the CNS areas more affected in patients 
with ALS and in animal models, placed cannabinoids as a possible and potential 
disease-modifying therapy in ALS [245][246]. 
 
5.1. The endocannabinoid system in Amyotrophic Lateral Sclerosis 
The levels of the endocannabinoids AEA and 2-AG are elevated in the spinal cord of 
SOD-1 mutant mice [247][248]. This was paralleled by an increase in the expression of 
NAPE-PLD, but no changes were observed in DAGL nor in FAAH and MAGL [249]. 
Increased levels of 2-AG in the spinal cord of these mice have been interpreted as an 
endogenous protective response, fueling the idea that inhibiting endocannabinoid-
inactivating enzymes may be neuroprotective in ALS [250]. CB2 receptors experienced 
an important upregulatory response in the spinal cord of SOD-1 mutant [251][249], 
TDP-43 transgenic [252] mice, in an ALS-related canine neurodegenerative pathology 
[253] and in patients with ALS [254][255]. This upregulation appears to occur 
predominantly in astrocytes recruited at lesioned sites in mutant SOD-1 mice 
(unpublished results), dogs with degenerative myelopathy [253], and postmortem 
primary motor cortex samples from patients with ALS [255]. CB2 receptor expression 




transgenic mice [252] and in postmortem spinal cord samples from patients with ALS 
[254]. These observations suggest that beneficial effects may be obtained by selectively 
targeting this receptor in the control of astrocyte support or microglial toxicity for motor 
neurons. Changes in the expression of CB1 receptors in animal models are inconclusive. 
A study reported downregulatory responses in the spinal cord of SOD-1 mutant mice, 
even at early presymptomatic phases [256], thus suggesting that it may predispose 
motor neurons to excitotoxic events, but these observations were not validated in the 
same mutant mice [249]. No changes in CB1 receptor expression were reported in the 
TDP-43 transgenic mice [252]. In the spinal cord of patients with ALS, CB1 receptors 
appear to be reduced [257]. 
 
5.2. Preclinical and clinical evidence for the therapeutic potential of cannabinoids in 
Amyotrophic Lateral Sclerosis 
Most pharmacological studies on the use of cannabinoids in experimental ALS were 
conducted in the classic transgenic mouse that overexpresses a mutated form (G93A) of 
SOD-1 despite mutations in this enzyme representing only a small percentage of ALS 
cases. The model was developed in the 1990s and was used to investigate the 
neuroprotective effects of ∆9-THC [258], cannabinol (CBN) [259], WIN 55,212-2 [248], 
and the selective CB2 agonist AM1241 [260][251], in all cases with beneficial effects. 
Similar findings were obtained from double mutants generated by crossing mutant 
SOD-1 mice with mice deficient in endocannabinoid genes FAAH or CB1 knockout 
mice [248]. These results reinforced not only the interest in using CB1 receptor agonists 
but also the elevation of endocannabinoid levels with FAAH inhibitors. Inhibition of 
MAGL in the same mutant SOD-1 mouse model delayed disease onset and progression 




cytokines and the elevation of BDNF in the spinal cord [250]. These effects were also 
reproduced in vitro [250]. Recent studies have extended the cannabinoid pharmacology 
to the new transgenic mouse model of TDP-43 (A315T). Activation of CB2 receptors 
improved motor behavior, preserved spinal motor neurons, and attenuated glial 
reactivity [261]. CB1 receptor activation also decreased glial reactivity but to a lower 
extent [261]. 
Clinical evidence for the use of cannabinoids in ALS is scarce. The first studies were 
exclusively observational, based on subjective impressions of patients with ALS who 
self-medicated with cannabis, and the results suggested a mild improvement for 
different symptoms [262]. A randomized, double-blind, crossover trial conducted with 
oral ∆9-THC showed that although the drug was well tolerated in patients, it failed to 
decrease the frequency and intensity of cramps [263][264]. No clinical studies have 
been attempted to investigate the potential of cannabinoids as disease-modifying 
therapies. There is an urgent need for additional clinical investigations in ALS, and 
cannabinoids might represent an interesting therapeutic approach [245]. 
 
5.3. Therapeutic implications for a cannabinoid-based therapy for Amyotrophic 
Lateral Sclerosis 
Research in cannabinoid-based neuroprotective therapies in ALS has been 
circumscribed to the preclinical level supporting the relevance of CB2 receptor 
activation on astrocyte trophic support, microglial reactivity, and neuroinflammation. It 
also involves certain CB1 receptor-mediated effects that might contribute to attenuate 
excitotoxic damage [265]. Cannabinoids with antioxidant properties (e.g., ∆9-THC, 
CBN) exerting a cannabinoid receptor-independent mechanism of action (perhaps 




studies are needed before reaching the clinic [265]. In this context, the potential of a 
Sativex-like combination of botanical extracts enriched in ∆9-THC and CBD was 
investigated in postsymptomatic SOD-1 mutant mice [249]. However, this combination 
provided a poor neurological recovery and no changes in animal survival [249], thus 
suggesting the need for additional cannabinoid combinations that demonstrate to be 
effective in preclinical models and that may be translated to the clinical scenario. 
 
6. Conclusions and future perspectives 
Cannabinoids are compounds with a broad spectrum of effects, which makes them 
suitable to target the multiple pathological features that characterize neurodegenerative 
diseases (Fig. 2). Currently, compounds with multiple targets or combinations of 
cannabinoids with different activities are being investigated. Preclinical studies provide 
evidence to support the potential of cannabinoid pharmacology for the treatment of 
these conditions. Each neurodegenerative disease has specific alterations of the ECS 
that will provide specific substrates for a cannabinoid-based therapy. With regard to this, 
an interesting experimental therapy for AD would be a 1:1 combination of ∆9-
THC:CBD because of the synergy existing between the mechanisms of action for each 
natural cannabinoid. The administration of both compounds was more effective than 
each single cannabinoid in reducing the cognitive decline and certain pathological 
processes. Moreover, available clinical data about the chronic use of a combination of 
∆9-THC and CBD for other indications suggest that it might result in a safe and well-
tolerated treatment for patients with AD and a virtual absence of the side effects 
commonly associated with the psychotropic properties of ∆9-THC owing to the capacity 
of CBD to counteract them. Interesting preclinical alternatives for the treatment of PD 




through the inhibition of their catabolic enzymes MAGL, which is neuroprotective, and 
FAAH. The phytocannabinoid ∆9-THCV with its particular profile has emerged as a 
valuable alternative, which needs to be further investigated. On the basis of the 
promising data on experimental models of HD, activation of CB1 and CB2 receptors 
would be the targets of choice for cannabinoid-based therapies, whereas cannabinoids 
targeting both receptors and also PPARγ would be the best option in ALS. Different 
strategies have been tested, directly targeting cannabinoid receptors with agonists or 
antagonists, or indirect modulation of the endocannabinoid signaling with inhibitors of 
endocannabinoid degradation or activation of cannabinoid-receptor independent effects. 
In fact, further research is needed to investigate one of the most interesting aspects of 
cannabinoid pharmacology, their neuroprotective profile, probably owing to their 
pleiotropic activity. The profound rearrangements experienced by the ECS during the 
time course of neurodegenerative diseases are specific for each disease and may vary 
through the different stages of the degenerative process. Because ECS changes are not 
homogeneous along the disease course and affect neuronal subsets differentially, similar 
therapeutic effects might be observed with drugs producing opposing actions or the 
same compound might produce both, thus amelioration or worsening of symptoms. An 
additional level of complexity is attributed to the functional selectivity of cannabinoids 
[177]. Different receptor agonists induce specific changes in receptor conformation, 
thereby activating different signaling pathways. Therefore, each class of cannabinoid 
receptor ligand needs to be evaluated separately for therapeutic efficacy. An important 
consideration that requires an in-depth investigation is the ability of cannabinoid 
receptors to form heteromers with other receptors generating unique signaling units that 
cannot be achieved by the individual receptors [153]. These heteromers contribute to the 




targets. PPARγ is one of the most relevant targets for CBD and other cannabinoids and 
a key element for exerting anti-inflammatory and neuroprotective properties [68]. The 
recent formulation of CBD as Epidiolex® (GW Pharmaceuticals, UK), which was 
approved by the Food and Drug Administration for the treatment of infantile refractory 
epileptic syndromes, may facilitate the use of this cannabinoid in clinical trials for 
neurodegenerative disorders. 
Consequently, further research is needed to identify the precise formulation for each 
type of pathology and each subset of patients as well as for achieving a neuroprotective 
effect. New clinical studies involving large samples of patients, placebo groups, 
appropriate molecular targets, and objective outcome measures are necessary to clarify 
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Figure 1: Versatility of the endocannabinoid system (ECS) elements to counteract the 
effects of aging and neurodegeneration. The ECS modulates common traits of 
neurodegeneration counteracting neuronal death, oxidative stress, neuroinflammation, 
or abnormal protein accumulation. The key location of the different ECS elements 
within the brain enables modulation of crucial processes for the correct balance between 
neuron survival and degeneration. Neurons express preferentially CB1 receptors 
involved in the regulation of neurotransmitter release. During the degenerative process, 
these receptors experience important alterations that may contribute to neuronal death. 
Resting microglia express low levels of CB2 receptors, and the levels were upregulated 
under pathological conditions. Targeting these receptors modulates neuroinflammatory 
responses. Astrocytes express low levels of CB1 receptors. Upon activation, they may 
modify the expression of either CB1 or CB2 receptor. The different cell types have the 
machinery for endocannabinoid biosynthesis, 2-arachidonoylglycerol (2-AG), or 
anandamide (AEA), thus contributing to the endocannabinoid tone of the brain. The 
specific contribution of each cell type may vary under different pathological conditions. 
 
Figure 2: Broad-spectrum profile of cannabinoids for the treatment of different 
neuropathological traits of neurodegenerative diseases. Beneficial effects of 
cannabinoid-based therapies determined from animal models of Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral 
sclerosis (ALS). Modulation in microglial immune responses showed a therapeutic 
response in AD, PD, HD, and ALS models. The antioxidant properties of cannabinoids 
were beneficial in animal models of AD and HD. In models of AD, targeting the 




aggregation and toxicity. Glutamatergic excitotoxicity was reversed by cannabinoid 
treatment in animal models of AD and HD. Endocannabinoid signaling modulation 
provides neuroprotection and disease modification in experimental models of PD, HD, 
and ALS.  
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